Clinical Trial Update: Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating chidamide as a single-agent therapy for relapsed or refractory B-cell non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Chidamide (chidamide)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) | Phase 2 | Status: UNKNOWN